Topical Finasteride and Topical Spironolactone as Options — Dr. Moriwaki Organizes How Topical Anti-Androgens and Stem Cell Conditioned Media Divide Roles2026.07.18

“I couldn’t tolerate oral finasteride” or “I’m worried about sexual side effects and struggle to continue it” — against the backdrop of such voices, topical finasteride and topical spironolactone, sometimes called “topical anti-androgens,” have recently drawn attention. They are designed to weaken dihydrotestosterone (DHT) activity locally on the scalp while minimizing systemic exposure, but their action is limited to the anti-androgen axis and they do not directly adjust the microenvironment around the hair follicle itself. In this article, Dr. Moriwaki organizes the positioning of these treatments in relation to hair regenerative medicine using stem cell conditioned media, and how the two divide roles.

Key Points of This Article

・Topical finasteride locally inhibits 5α-reductase type II on the scalp and suppresses DHT production as a topical anti-androgen

・Topical spironolactone competitively blocks the androgen receptor and is often chosen for women

・”Topical anti-androgens” do not stimulate hair follicles to grow; they are “subtractive” treatments that suppress DHT’s excessive influence

・Stem cell conditioned media scalp treatment is an “additive” concept that delivers growth factors and cytokines to the follicular microenvironment, aiming at a different target than anti-androgens

・The two are complementary rather than competitive, but the design must consider side effects, pregnancy possibility, cost, and adherence

What Is Topical Finasteride — the “Topical DHT Suppression” Concept

Mechanism of Action

Finasteride inhibits 5α-reductase type II, blocking the conversion of testosterone to DHT, and thereby slows the miniaturization of hair follicles in AGA. The topical formulation applied locally to the scalp has been developed to reduce local scalp DHT concentration while keeping systemic blood DHT reduction to a minimum. Because systemic exposure is smaller compared to oral use, it can serve as an option for men who are concerned about sexual side effects.

Absorption and Systemic Transfer

That said, some of the components applied to the scalp enter systemic circulation through the skin. Depending on application volume, area, and post-application contact, systemic blood DHT has been reported to decrease to some degree, so the misconception that “topical means zero side effects” should be avoided. Women who may become pregnant must avoid contact, and instructions covering shared bathroom management, hand washing after application, and pillowcase handling are necessary.

Topical Spironolactone as an Option

Mechanism and Main Indications

Spironolactone was originally a diuretic, but it also competitively blocks the androgen receptor, and oral use has historically been applied to FAGA (female-pattern hair loss). Topical spironolactone delivers this drug directly to the scalp, aiming to dull local follicular androgen sensitivity while minimizing systemic effects on electrolytes and blood pressure. Because its action point is the receptor rather than 5α-reductase, it holds a complementary position to finasteride.

Different Positioning for Men and Women

For male AGA, topical finasteride tends to be the primary candidate, whereas for women, finasteride is generally not usable, so topical spironolactone is chosen more often. However, in female diffuse hair loss, non-androgen factors such as iron deficiency or thyroid dysfunction are often the main culprit, and the shortcut of “start with a topical anti-androgen” should be avoided in the treatment design. It should be judged only after understanding the systemic background through blood tests.

How Topical Finasteride and Stem Cell Conditioned Media Divide Roles

While “topical anti-androgens” are subtractive treatments that reduce DHT’s excessive influence, hair regenerative medicine using stem cell conditioned media is an “additive” concept that delivers growth factors and cytokines to the microenvironment around the hair follicle. Because their targets differ, the two are complementary rather than competitive. Suppressing progression with an anti-androgen while adjusting inflammation, blood flow, and fibrosis around the follicle with conditioned media — such a combination is sometimes considered for cases that have plateaued on monotherapy. For related treatment design, please also see our hair regenerative medicine column index here.

How to Estimate Safety and Adherence

Skin irritation, contact dermatitis, and scalp itching have been reported with topical finasteride, and redness and dryness with topical spironolactone. For the positioning of drug therapy for AGA and FAGA, referring to the male- and female-pattern hair loss guidelines of the Japanese Dermatological Association helps grasp the current state of the evidence. Because topical treatment requires daily effort over time, unless adherence, cost, and side effects are all planned in advance, treatment tends to stop midway and effect assessment becomes impossible. Deciding the assessment period (typically 3–6 months) and evaluation method (photographs, microscope) before starting is a prerequisite for continuing efficiently.

Frequently Asked Questions

Q. Does topical finasteride work as well as the oral form?

Individual variation is large; some studies show density improvement close to that of the oral form, but head-to-head evidence remains limited. Position it as an option for those wishing to minimize systemic effects, and evaluate objectively with standardized photographs and microscope images at 3–6 months.

Q. Can women use “topical anti-androgens”?

For women of reproductive potential, finasteride is essentially treated as contraindicated. Even topical use partly enters systemic circulation and can affect the development of male fetal external genitalia. If considering anti-androgens for women, please discuss alternatives such as topical spironolactone with your physician.

Q. Is there value in combining with stem cell conditioned media?

Because their action axes differ, combining progression suppression (anti-androgen) with microenvironment improvement (conditioned media) is a rational design. However, more treatments add cost and clinic visit burden, so it is important to set priorities and evaluation periods at the start.

Q. Should I stop the topical drug immediately if itching occurs?

If mild, it may be possible to continue by changing the base or adjusting application frequency. If there is strong redness, blistering, or widespread eczema, contact dermatitis is possible — do not continue on your own judgment; please consult your treating physician.

──────────────

【Medical Supervisor】Shin Moriwaki (Supervising Physician)

Member, Japan Society of Aesthetic Surgery (JSAS) / Member, American Academy of Aesthetic Medicine

ECFMG Certificate (U.S. Medical Licensing Qualification)

──────────────

📍AVAN TOKYO Ginza Hair Regenerative Medicine

AVAN TOKYO Ginza Hair Regenerative Medicine

English / 中文 / Tiếng Việt available

Inquiries welcome via DM / LINE / Website / Phone.